Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant ...

Retinal implants have gained increasing interest since it was demonstrated in acute trials that completely blind subjects do have light perception upon electrical stimulation of the inner surface ...

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

A rare, progressive neurodegenerative disease associated with loss of macular photoreceptors in the retinas, MacTel type 2 ...

Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.

Sadly, for a group reliant on retinal implants from company Second Sight, the company has since stopped producing and supporting the devices that give them a crude form of bionic sight.

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

While there is currently no cure for RP, certain treatments such as gene therapy, retinal implants, and vitamin A supplementation can help slow its progression. Ongoing research in areas like stem ...

Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, announced that the U.S. Food and Drug Administration (FDA), has ...

But with the help of a retinal implant, or "bionic eye" called Argus II, some patients with the rare disorder are regaining their sight. A clinical trial of the device has been ongoing in 10 ...

we examined the surgical outcomes of patients with glaucoma requiring a scleral buckle for retinal detachment repair who underwent concomitant scleral buckle and Baerveldt glaucoma implant (BGI ...